174 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
9 May 24
Akebia Therapeutics Reports First Quarter 2024 Financial Results
7:03am
potential and acceptance of, as well as coverage and reimbursement related to, Auryxia® and Vafseo, including estimates regarding the potential market
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to, Auryxia® and Vafseo, including estimates
8-K
AKBA
Akebia Therapeutics Inc.
15 Mar 24
Departure of Directors or Certain Officers
4:05pm
of base salary continuation and, provided she timely elects COBRA coverage, up to 12 months of reimbursement of a portion of her and her dependents
8-K
EX-99.1
kdrsb6yb8sn
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
p1mda5jrcz3v86o 2r
8 Jan 24
Results of Operations and Financial Condition
8:02am
8-K
EX-99.1
86p8w5gl
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
EX-99.1
o8rh5hv6lmuil s9qc
25 Oct 23
Akebia Receives FDA Acceptance of Resubmission to NDA of
4:06pm
8-K
EX-99.1
uykabtsyqvfkobf4w3
26 Sep 23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
4:47pm